From Nasdaq.: 2025-06-15 12:25:00

Sanofi and Regeneron Pharmaceuticals presented positive results from the EVEREST Phase 4 study showing Dupixent outperformed Xolair in treating severe chronic rhinosinusitis with nasal polyps and asthma. The study confirmed Dupixent’s effectiveness in targeting IL-4 and IL-13 to address type 2 inflammation in both upper and lower respiratory diseases.

Safety results from the study revealed similar overall rates of adverse events between Dupixent and omalizumab, with serious AEs reported in 2% and 4% of patients, respectively. AEs leading to study discontinuation were reported in 3% of Dupixent patients and 1% of omalizumab patients.



Read more at Nasdaq.: Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment